

Cetuximab

Study of cetuximab as a single agent in patients with recurrent and/or metastatic SCCHN who failed to respond to platinum-based therapy

Study of cetuximab as a single agent in patients with recurrent and/or metastatic SCCHN who failed to respond to platinum-based therapy

Cetuximab Study of cetuximab as a single agent in patients with recurrent and/or metastatic SCCHN who failed to respond to platinum-based therapy

Cetuximab Study of cetuximab as a single agent in patients with recurrent and/or metastatic SCCHN who failed to respond to platinum-based therapy


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

NEB



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

NEB



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer

Therapeutic Indication: Recurrent or metastatic SCCHN progressing after platinum-based therapy

Experimental Arm: Cetuximab

Control Arm: Single arm



